HUI-GENE THERAPEUTICS
Hui-Gene is focused on R&D for single-gene disorders and has developed pilot pipes in neurodegenerative diseases.
HUI-GENE THERAPEUTICS
Industry:
Biopharma Biotechnology Genetics Life Science Medical Medical Device Pharmaceutical Therapeutics
Founded:
2018-10-01
Address:
Shanghai, Shanghai, China
Country:
China
Website Url:
http://www.huidagene.com
Total Employee:
11+
Status:
Active
Contact:
15221536625
Email Addresses:
[email protected]
Total Funding:
14.21 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Mobile Non Scaleable Content Nginx Euro Microsoft Azure DNS Apple Mobile Web App Capable Pound Sterling
Similar Organizations
Cerevance
Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.
GigaGen
GigaGen specialized in the early discovery and development of recombinant biotherapeutic medicines.
Nurix Therapeutics
Nurix Therapeutics is a biopharmaceutical company that focuses on the development and discovery of small molecule drugs.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Current Employees Featured
Founder
Investors List
CD Capital
CD Capital investment in Series C - Hui-Gene Therapeutics
Kunlun Capital
Kunlun Capital investment in Series C - Hui-Gene Therapeutics
Sherpa Venture Capital
Sherpa Venture Capital investment in Series C - Hui-Gene Therapeutics
Mayo Clinic Ventures
Mayo Clinic Ventures investment in Series A - Hui-Gene Therapeutics
WuXi AppTec
WuXi AppTec investment in Series A - Hui-Gene Therapeutics
Hillhouse Capital Group
Hillhouse Capital Group investment in Series A - Hui-Gene Therapeutics
Huimei Capital
Huimei Capital investment in Series A - Hui-Gene Therapeutics
Sherpa Venture Capital
Sherpa Venture Capital investment in Series A - Hui-Gene Therapeutics
CD Capital
CD Capital investment in Series A - Hui-Gene Therapeutics
Official Site Inspections
http://www.huidagene.com
- Host name: 114.55.227.74
- IP address: 114.55.227.74
- Location: Hangzhou China
- Latitude: 30.294
- Longitude: 120.1619
- Timezone: Asia/Shanghai
More informations about "Hui-Gene Therapeutics"
About us-HUIDAGENE
About Us HuidaGene is a global clinical-stage biotechnology company focusing on discovering, engineering, and developing gene editing tools and gene therapies to rewrite the future of genomic medicine. Based in Shanghai and …See details»
HuidaGene-HUIDAGENE
HuidaGene is a global clinical-stage biotechnology company focusing on discovering, engineering, and developing gene editing tools and gene therapies to rewrite the future of …See details»
HuidaGene Therapeutics - Crunchbase Company Profile & Funding
HuidaGene is a global clinical-stage biotechnology company pioneering innovative gene therapies for neurology and ophthalmology.See details»
HuidaGene Therapeutics - LinkedIn
HuidaGene Biotechnology Co., Ltd (辉大基因) is a global clinical-stage biotechnology company focusing on the discovering, engineering, and developing CRISPR-based gene-editing tools and gene ...See details»
辉大基因-HUIDAGENE
辉大基因是一家全球性的临床阶段生物技术公司，专注于设计、改造及开发新型CRISPR基因编辑工具和颠覆性的创新基因疗法。总部位于中国上海，并在美国新泽西设有办公室，辉大基因目标是利用基因编辑技术满足全球患者的切实需 …See details»
HuidaGene Therapeutics Co., Ltd. - Drug pipelines, …
SHANGHAI, China and CLINTON, NJ, USA I November 4, 2024 I HuidaGene Therapeutics (“HuidaGene”), a global clinical-stage biotechnology company, announced that the U.S. FDA has cleared its investigational new drug (IND) …See details»
Leadership-HUIDAGENE
Hui Yang, Ph.D., is the Co-Founder and Chief Scientific Advisor of HuidaGene and currently serves as Principal Investigator at Center for Excellence in Brain Science and Intelligence Technology of the Chinese Academy of Sciences …See details»
管理团队-HUIDAGENE
在动物疾病模型开发与验证、基因编辑工具优化、病毒载体工程与设计以及生产工艺开发等方面，拥有超过10年的临床前开发和转化科学经验。 带领团队进行超过10个早期药物发现研究、6个管线临床前研究和20多个AAV衣壳筛选项目，并 …See details»
关于我们-HUIDAGENE
关于我们 辉大基因是一家全球性的临床阶段生物技术公司，专注于设计、改造及开发新型CRISPR基因编辑工具和颠覆性的创新基因疗法。总部位于中国上海，并在美国新泽西设有办 …See details»
HuidaGene Therapeutics - Funding, Financials, Valuation & Investors
HuidaGene is a global clinical-stage biotechnology company pioneering innovative gene therapies for neurology and ophthalmology.See details»
Company: HuidaGene Therapeutics - CRISPR Medicine
HuidaGene is a global clinical-stage biotechnology company focusing on discovering, engineering, and developing gene-editing tools and gene therapies develop novel genetic …See details»
HuidaGene Therapeutics Co., Ltd. (辉大（上海）生物科技有限公 …
Global clinical-stage biotech company HuidaGene Therapeutics has received FDA clearance to move forward with its application for its investigational drug, a CRISPR/Cas13 RNA-editing …See details»
Raising Awareness for Rare Diseases: A Global Movement for …
Feb 27, 2025 HuidaGene's Commitment to Rare Diseases At HuidaGene Therapeutics, we are proud to be at the forefront of innovative gene therapies for rare diseases.See details»
HuidaGene Therapeutics to Present at Multiple Key Conferences ...
Mar 3, 2025 HuidaGene will present advancements in CRISPR-based gene-editing and RNA-targeting therapies at these conferences. HuidaGene’s presentations will showcase the latest …See details»
更名声明 | 辉大基因英文名称正式变更为HuidaGene Therapeutics
Feb 14, 2023 辉大（上海）生物科技有限公司（简称“辉大基因”）宣布，自2023年1月28日起，公司英文名称从原来的“HuiGene Therapeutics Co., Ltd.”正式变更为“HuidaGene Therapeutics …See details»
HuidaGene Therapeutics Receives the First-Ever FDA Clearance of …
Nov 4, 2024 HuidaGene Therapeutics ("HuidaGene"), a global clinical-stage biotechnology company, announced that the U.S. FDA has cleared its investigational new drug (IND) …See details»
参会速递 | 辉大基因将参加2024年美国生物技术大会暨展览会-公司 …
May 31, 2024 大会由美国生物技术创新组织机构 (Biotechnology Innovation Organization，“BIO”)主办，BIO是代表生物技术公司、学术机构和相关机构的全球最大生物技 …See details»
HuidaGene Therapeutics Receives the First-Ever FDA Clearance of …
Nov 5, 2024 Primary endpoints include the safety and tolerability of HG202, with secondary endpoints assessing improvements in visual acuity, retinal thickness, and the need for anti …See details»
辉大基因将在全球重要会议上展示CRISPR基因编辑疗法的突破性进 …
4 days ago 上海和中城（美国特拉华州），2025年4月1日—专注于基因治疗药物开发、处于临床阶段的全球性生物技术公司—辉大（上海）生物科技有限公司（简称“辉大基因”）今天宣布将 …See details»
辉大基因RNA编辑疗法HG204研究成果发表于Nature子刊《自然神 …
上海和中城（美国特拉华州），2024年12月12日 –专注于基因治疗药物开发的全球性临床阶段生物技术公司——辉大（上海）生物科技有限公司（简称“辉大基因”），宣布其关于CRISPR RNA …See details»